Lack of prognostic significance of the germinal-center phenotype in diffuse large B-cell lymphoma patients treated with CHOP-like chemotherapy with and without rituximab

Ilić, Ivana; Mitrović, Zdravko; Aurer, Igor; Bašić-Kinda, Sandra; Radman, Ivo; Ajduković, Radmila; Labar, Boris; Dotlić, Snježana; Nola, Marin

doi:10.1007/s12185-009-0353-y

Pregled bibliografske jedinice broj: 452022

Lack of prognostic significance of the germinal-center phenotype in diffuse large B-cell lymphoma patients treated with CHOP-like chemotherapy with and without rituximab

Ilić, Ivana; Mitrović, Zdravko; Aurer, Igor; Bašić-Kinda, Sandra; Radman, Ivo; Ajduković, Radmila; Labar, Boris; Dotlić, Snježana; Nola, Marin

Lack of prognostic significance of the germinal-center phenotype in diffuse large B-cell lymphoma patients treated with CHOP-like chemotherapy with and without rituximab // International journal of hematology, 90 (2009), 1; 74-80 doi:10.1007/s12185-009-0353-y (međunarodna recenzija, članak, znanstveni)

CROSBI ID: 452022 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Lack of prognostic significance of the germinal-center phenotype in diffuse large B-cell lymphoma patients treated with CHOP-like chemotherapy with and without rituximab

Autori
Ilić, Ivana ; Mitrović, Zdravko ; Aurer, Igor ; Bašić-Kinda, Sandra ; Radman, Ivo ; Ajduković, Radmila ; Labar, Boris ; Dotlić, Snježana ; Nola, Marin

Izvornik
International journal of hematology (0925-5710) 90 (2009), 1; 74-80

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
lymphoma; non-Hodgkin; large b-cell diffuse lymphoma; immunohistochemistr; rituximab; CHOP chemotherapy

Sažetak
The influence of the germinal-center B-cell (GCB) and the non-GCB phenotypes of diffuse large B-cell lymphoma (DLBCL) on the outcome of 92 patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like chemotherapy, with or without rituximab was determined in this study. The differentiation between the GCB and non-GCB types was arrived at by immunohistochemistry using previously published criteria. Thirty-nine patients had the GCB and 53 had the non-GCB type of DLBCL. Forty-nine patients were treated with rituximab and chemotherapy ; 43 were treated with chemotherapy alone. The GCB and non-GCB group did not differ in their international prognostic index factors and score, presence of bulky disease, or frequency of rituximab treatment. Median follow-up of the surviving patients was carried out for 37 months. There was no difference between the GCB and non-GCB groups in both overall response rates (67 vs. 70%, respectively) and estimated rates of 3-year event-free (46 vs. 49%, respectively) and overall (54 vs. 56%, respectively) survival. In addition, no differences of the outcomes were observed between the subgroups treated with or without rituximab. The patients of this study with immunohistochemically determined GCB-type DLBCL did not have an improved prognosis, irrespective of whether they had received rituximab or not.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti

POVEZANOST RADA

Projekti:
108-0000000-3426 - CD 43 - prognostički biljeg za predviđanje ishoda oboljelih od limfoma (Ilić, Ivana, MZOS ) ( CroRIS)
108-1081872-1908 - Dijagnostika i liječenje limfoma (Aurer, Igor, MZOS ) ( CroRIS)
108-1081872-1913 - LEUKEMIJE I TRANSPLANTACIJA KRVOTVORNIH MATIČNIH STANICA (Duraković, Nadira, MZOS ) ( CroRIS)

Ustanove:
Medicinski fakultet, Zagreb

Profili:

Boris Labar (autor)